BRNS Stock Analysis: Buy, Sell, or Hold?
BRNS - Barinthus Biotherapeutics plc American Depositary Shares
$0.62
-0.02 (-3.26%)
▼
5d:
-13.76%
30d:
-8.9%
90d:
+8.98%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When BRNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BRNS is down 13.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BRNS is down 13.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BRNS is currently trading at $0.62, which is considered oversold relative to its 30-day fair value range of $0.66 to $0.71.
Technical Outlook: Technically, BRNS is in a uptrend. Immediate support is located at $0.59, while resistance sits at $0.77. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+787.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BRNS is in a uptrend. Immediate support is located at $0.59, while resistance sits at $0.77. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+787.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.66 -
$0.71
Company Quality Score
55/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 787.0% below Wall St target ($5.50)
- WARNING: Recommendation downgraded due to -13.8% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.66 -
$0.71
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.59
Resistance Level
$0.77
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.54
Wall Street Target
$5.50
(+787.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 02, 2026 10:48 PM ET
Data refreshes hourly during market hours. Next update: 11:48 PM
Data refreshes hourly during market hours. Next update: 11:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BRNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
